Peptide Therapy News: Market Surge Driven by GLP-1 Innovation and Brand Competition
Abstract: The peptide therapy market is surging, driven by GLP-1 innovation and brand competition. Market data reveals a CAGR exceeding 8%, with semaglutide and tirzepatide dominating. Brand differentiation hinges on purity (>99%) and stability. GLP-1s excel in glycemic control/weight loss, while other peptides target anti-aging. Key advantages include high specificity; disadvantages include short half-lives. Product parameters (e.g., sequence, salt form) and certificates (COA, GMP) are critical for selection. Logistics require cold-chain compliance. Industry trends favor oral delivery and novel targets.